Intra-Cellular Therapies (ITCI) '007 Seen as Approvable by KOL - Piper Jaffray

October 10, 2016 7:44 AM EDT
Get Alerts ITCI Hot Sheet
Price: $13.58 -1.95%

Rating Summary:
    7 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ITCI Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and $22 price target on Intra-Cellular Therapies (NASDAQ: ITCI) after the company hosted a call with a psychiatry KOL experienced in schizophrenia treatment and drug development. The doctor sees ‘007 as approvable.

Duncan commented, "While we discussed the potential reasons behind the recent 302 failure, including expectation bias and patient quality, the big take-away is that this doctor sees ‘007 as approvable based on the two existing positive trials (005+301, with supportive observations from 302). This perspective reinforces our out-of-consensus view that the FDA may not require Intra-Cellular to run another trial prior to NDA submission. We believe the FDA may view the existing evidence of anti-psychotic activity and differentiated tolerability from ‘007 as compelling. We also think the common occurrence of failed trials for effective agents in CNS drug development is well-understood by FDA and that 302 will be evaluated in that context. Overall, we see a buying opportunity for patient investors and in advance of regulatory updates and data presentations as soon as YE16, we reiterate OW."

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $15.15 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Piper Jaffray, The Children's Investment Fund (TCI), Charles Duncan

Add Your Comment